Huaxi Securities maintains Buy for WuXi AppTec stock
Published on 10/14/2026 at 10:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGuidance and reporting timetable
- Huaxi Securities maintained its Buy rating on October 14, 2026.
- First-half revenue reached RMB 28.897 billion, up 38.93 percent year over year.
- WuXi AppTec stock was trading at EUR 23.05 at 10:34 a.m. CEST at Lang & Schwarz on October 14, 2026.
- The next earnings report is scheduled for October 26, 2026.
WuXi AppTec stock was at EUR 23.05 at Lang & Schwarz on October 14, 2026, while Huaxi Securities maintained its Buy rating in a report dated October 14, 2026. The report cited first-half revenue of RMB 28.897 billion, up 38.93 percent year over year, and a higher full-year revenue outlook.
Three dated developments
On July 21, 2026, WuXi AppTec said it had entered the FTSE4Good Index Series for the fourth consecutive year. On October 7, 2026, the company reported its third consecutive EcoVadis Gold medal through the same investor information page. On October 14, 2026, GMT EIGHT reported that Huaxi Securities maintained its Buy rating and cited revised 2026 guidance.
What does guidance change?
Huaxi Securities reported that WuXi AppTec lifted its 2026 total revenue guidance from RMB 51.3 billion-53.0 billion to RMB 58.5 billion-60.5 billion. The continuing-operations growth range also moved from 18 percent-22 percent to 35 percent-39 percent, a wider improvement in the operating outlook than the stock quote alone suggests.
The same report said the first-half adjusted net profit margin was expected to remain relatively stable. For investors, the key issue is whether higher revenue converts into durable earnings while the company expands capacity and serves later-stage drug programs.
Revenue and backlog carry weight
WuXi AppTec generated RMB 28.897 billion in revenue during the first half of 2026, while net profit attributable to shareholders reached RMB 11.08 billion, up 29.43 percent year over year, according to GMT EIGHT. Sustained-business backlog stood at RMB 59.77 billion at the end of June 2026, up 23.6 percent year over year.
The D&M business contributed RMB 14.99 billion in first-half revenue, an increase of 72.7 percent year over year, according to GMT EIGHT. That mix matters because it links the headline guidance revision to a specific operating engine rather than to a purely financial adjustment.
Results date and market quote
The next earnings report is listed for October 26, 2026, by Investing.com. The scheduled report gives the market a near-term test for the raised revenue range and for the backlog conversion described in the October 14 report.
EUR 23.05 at Lang & Schwarz
WuXi AppTec was trading at EUR 23.05 at Lang & Schwarz on October 14, 2026 at 10:34 a.m. CEST. The quote is an intraday level, while the next dated company event is the October 26, 2026 earnings report.
The further course of trading is shown by the continuously updated real-time quote of WuXi AppTec stock.
WuXi AppTec stock facts
- Company: WuXi AppTec Co., Ltd.
- ISIN: CNE100003F19
- Ticker: 2359
- Primary exchange: Hong Kong Stock Exchange
- Price Lang & Schwarz (as of October 14, 2026, 10:34 a.m. CEST): EUR 23.05
- Sector / Industry: Healthcare / Biotechnology and Medical Research
- Next earnings date: October 26, 2026
Market context: Latest market reports.
